Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
| (NASDAQ: KPRX) | Delayed: 2.53 -0.03 (1.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.56 | 52 Week High | $ | |||
| Open | $2.56 | 52 Week Low | $ | |||
| Day High | $2.57 | P/E | N/A | |||
| Day Low | $2.52 | EPS | $ | |||
| Volume | 8,569 | |||||
